Wealth Enhancement Advisory Services
BCRX icon

Wealth Enhancement Advisory Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$681K Buy
65,149
+52,827
+429% +$478K ﹤0.01% 2402
2026
Q1 		$111K Sell
12,322
-3,696
-23% -$28.7K ﹤0.01% 3297
2025
Q4 		$121K Sell
16,018
-5,806
-27% -$42K ﹤0.01% 3393
2025
Q3 		$152K Sell
21,824
-15,942
-42% -$133K ﹤0.01% 3230
2025
Q2 		$338K Buy
37,766
+95
+0.3% +$885 ﹤0.01% 2551
2025
Q1 		$283K Buy
37,671
+20,043
+114% +$162K ﹤0.01% 2489
2024
Q4 		$133K Buy
17,628
+284
+2% +$2.16K ﹤0.01% 2762
2024
Q3 		$132K Buy
17,344
+5,340
+44% +$40.6K ﹤0.01% 2510
2024
Q2 		$74.2K Buy
12,004
+743
+7% +$4.1K ﹤0.01% 2435
2024
Q1 		$57.2K Buy
+11,261
New +$63.3K ﹤0.01% 2335
2023
Q4 		– Sell
-12,554
Closed -$88.9K – 2349
2023
Q3 		$88.9K Buy
+12,554
New +$90.2K ﹤0.01% 2112

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Wealth Enhancement Advisory Services's BCRX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its BioCryst Pharmaceuticals (BCRX) stake by 429% in Q2 2026, buying an estimated $478K and bringing the position to 65,149 shares worth $681K. The position accounts for ﹤0.01% of the portfolio, ranked #2402.

Wealth Enhancement Advisory Services first reported a position in BCRX in Q3 2023 and has held it in 11 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 65,149 shares of BioCryst Pharmaceuticals worth $681K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 52,827 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $478K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2402 holding.
  • Wealth Enhancement Advisory Services first reported a position in BioCryst Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.